Funding
Nutromics banks A$7.5m to make its ‘lab-on-a-patch’ device in Australia
Nutromics’ latest raise adds fuel to its push for continuous molecular monitoring in the ICU, with vancomycin the first target and a local advanced-manufacturing play on the table.
